Rx Products (December 2017)

DECEMBER 28, 2017


BYDUREON BCISE
MANUFACTURED BY: AstraZeneca
INDICATION: The FDA has approved AstraZeneca’s Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type 2 diabetes whose blood sugar remains uncon- trolled on 1 or more oral medicines, in addition to diet and exercise, to improve glycemic control.
DOSAGE: Extended-release injectable suspension
FOR MORE INFORMATION: astrazeneca.com



LYRICA CR
MANUFACTURED BY: Pfizer, Inc.
INDICATION: The FDA has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily therapy of neuropathic pain associated with diabetic peripheral neuropathy and the management of postherpetic neuralgia.
DOSAGE: Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg
FOR MORE INFORMATION: Pfizer.com



FIASP
MANUFACTURED BY: Novo Nordisk
INDICATION: The FDA has approved Fiasp (fast-acting insulin aspart), a fast-acting mealtime insulin, for the treatment of adults with type 1 and 2 diabetes.
DOSAGE: Injection: 100 units/mL
FOR MORE INFORMATION: novonordisk-us.com



YESCARTA
MANUFACTURED BY: Kite Pharma
INDICATION: The FDA has approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients
with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least 2 other kinds of treatment.
DOSAGE: Cell suspension for infusion
FOR MORE INFORMATION: kitepharma.com

SHARE THIS
36